Journal History

2011 The inaugural issue was released. JPM was published as a quarterly journal.
The first Special Issue “Recent Advances in Personalized Medicine” was announced.
2013 JPM was indexed in Scopus/SciVerse.
2014 JPM was indexed in PubMed and PubMed Central (PMC).
2016 JPM announced the first edition of the Travel Awards.
2018 JPM was indexed in Emerging Sources Citation Index (ESCI) - Web of Science (Clarivate Analytics).
JPM received CiteScore of 2.62, ranked 54/189 (Q1) in 'Medicine (miscellaneous)'.
2019 JPM was indexed in Science Citation Index Expanded (SCIE) - Web of Science (Clarivate Analytics), ranked in Q1.
2020 JPM received its First Impact Factor (4.433), ranked 10/102(Q1) in the category "Health Care Sciences & Services", 24/165(Q1) in the category "Medicine, General & Internal".
2021 JPM adopted a monthly publication schedule.
JPM received 2020 Impact Factor (4.945), ranked 15/108(Q1) in the category " Health Care Sciences & Services", 31/169(Q1) in the category "Medicine, General & Internal".
2022 JPM received 2021 Impact Factor (3.508), covered in the category " Health Care Sciences & Services" and "Medicine, General & Internal".
JPM organized the first webinar "Radiation Response Biomarkers for Individualised Cancer Treatments".
JPM established the following sections:
-Personalized Therapy and Drug Delivery;
-Evidence Based Medicine;
-Regenerative Medicine and Therapeutics;
-Epigenetic Therapy;
-Sex, Gender and Hormone Based Medicine.
2023 JPM has established the following sections:
-Disease Biomarker;
-Life Stage Specific Medicine (LSSM);
-Personalized Critical Care;
-Molecular Targeted Therapy.


2011–2015  Editor-in-Chief: Prof. Dr. Urs A. Meyer
2015–2021 Editor-in-Chief: Prof. Dr. Stephen B. Liggett
2021–present  Editor-in-Chief: Prof. Dr. David Alan Rizzieri

Section Editor-in-Chief

2021–2023 Section Editor-in-Chief: Prof. Dr. Richard E. Frye for the section on Mechanisms of Diseases
2021–present  Section Editor-in-Chief: Prof. Dr. Enrico Mini for the section on Pharmacogenetics
Section Editor-in-Chief: Prof. Dr. Kenneth P.H. Pritzker for the section on Clinical Medicine, Cell, and Organism Physiology
Section Editor-in-Chief:
Prof. Dr. K. Ray Chaudhuri for the section on Methodology, Drug and Device Discovery
2022–present  Section Editor-in-Chief: Prof. Dr. Salvatore Scacco for the section on Omics/Informatics
Section Editor-in-Chief: 
Prof. Dr. Marijn Speeckaert for the section on Epidemiology
Section Editor-in-Chief: 
Prof. Dr. Liang Cheng for the section on Personalized Therapy and Drug Delivery
Section Editor-in-Chief:
 Prof. Dr. Taulant Muka for the section on Evidence Based Medicine
2023–present Section Editor-in-Chief: Prof. Dr. Anat Biegon for the section on Sex, Gender and Hormone Based Medicine
Section Editor-in-Chief:
 Prof. Dr. Lorenza Rimassa for the section on Disease Biomarker
Section Editor-in-Chief: 
Prof. Dr. Weikuan Gu for the section on Life Stage Specific Medicine (LSSM)
Back to TopTop